1

2

3
Smith Gary Keith, Duch David Stanley, Ferone Robert, Koch Arthur: Nouvelle combinaison dantifolates et de benzoquinazoline, utilisee comme agent protecteur, Novel combination of benzoquinazoline antifolates and protecting agents. The Wellcome Foundation, The Wellcome Foundation, OGILVY RENAULT SENCRLSRL, July 7, 1994: CA2152507

The use of a protecting agent, for example a folate derivative such as folic acid or leucovorin, in combination with a non-competitive folic acid analogue, for example benzoquinazoline derivatives, for use in reducing the side effects associated with the administration of such non-competitive folic ...


4
Bigham Eric Cleveland, Nichol Charles Adam, Reinhard John Frederick Jr, Smith Gary Keith: Analogues de pteridine ayant une action neurologique, Neurologically active pteridine analogues. Wellcome Foundation, OGILVY RENAULT SENCRLSRL, August 27, 1991: CA1288099

Abstract The use of compounds of the formula (I): Imageor pharmaceutically acceptable salts or bio-precursors thereof;wherein R1 is hydrogen, C1-4 alkyl, C2-4 alkenyl, a group -BX(R5)n, or -BZBX(R5) wherein Z and X (when n=1) are the same or different and each is -O,-S(O)q or -NR6- wherein q is 0, 1 ...


5
Andrews Clarence W, Cheung Mui, Davis Ward Ronda G, Drewry David Harold, Emmitte Kyle Allen, Hubbard Robert Dale, Kuntz Kevin W, Linn James Andrew, Mook Robert Anthony, Smith Gary Keith, Veal James Marvin: Benzimidazol-1-yl-thiophene compounds for the treatment of cancer. Smithkline Beecham, June 29, 2005: EP1546137-A1

The present invention provides compounds of formula (I): (I) pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.


6
Smith Gary Keith, Duch David Stanley, Ferone Robert, Koch Arthur: Novel combination of benzoquinazoline antifolates and protecting agents. The Wellcome Foundation, Smith Gary Keith, Duch David Stanley, Ferone Robert, Koch Arthur, ROLLINS Anthony John, July 7, 1994: WO/1994/014448

The use of a protecting agent, for example a folate derivative such as folic acid or leucovorin, in combination with a non-competitive folic acid analogue, for example benzoquinazoline derivatives, for use in reducing the side effects associated with the administration of such non-competitive folic ...


7
Smith Gary Keith: Bunyaviridal reaper proteins and uses therefor. Glaxo Group, Smith Gary Keith, LEVY David J, August 30, 2001: WO/2001/062936

Viral proteins with sequence and functional similarity to the drosophila cell death protein known as Reaper are provided. Reaper plays an important role in the apoptotic pathway. Methods using the viral proteins and nucleotides encoding such proteins are described.


8
Smith Gary Keith, Blumenkopf Todd Andrew, Cory Michael: Therapy. The Wellcome Foundation, Smith Gary Keith, Blumenkopf Todd Andrew, Cory Michael, STOTT Michael John, May 18, 1995: WO/1995/013095

The present invention relates to improvements in targetted enzyme prodrug therapy including antibody-directed enzyme prodrug therapy (ADEPT), it particularly relates to novel enzymes and prodrugs for use in ADEPT.


9
Smith Gary Keith: Bunyaviridal reaper proteins and uses therefor. Glaxo Group, November 27, 2002: EP1259617-A2

Viral proteins with sequence and functional similarity to the drosophila cell death protein known as Reaper are provided. Reaper plays an important role in the apoptotic pathway. Methods using the viral proteins and nucleotides encoding such proteins are described.


10
Smith Gary Keith, Blumenkopf Todd Andrew, Cory Michael: Therapy. Wellcome Found, August 28, 1996: EP0728018-A1

The present invention relates to improvements in targetted enzyme prodrug therapy including antibody-directed enzyme prodrug therapy (ADEPT), it particularly relates to novel enzymes and prodrugs for use in ADEPT.